Skip to content

NRX Pharmaceuticals, Inc.

NRXP

CIK 0001719406

← back to feed
Revenue (TTM)
$1.31M
Q1 May 2026
Net Income (TTM)
−$30.41M
−13.9% YoY Q1 May 2026
EPS Diluted (TTM)
−$2.59
+69.7% YoY Q1 May 2026
Gross Margin
44.4%
Q1 May 2026
Operating Margin
-1,247.6%
Q1 May 2026
Net Margin
-2,321.6%
Q1 May 2026
Free Cash Flow (TTM)
−$17.54M
Q1 May 2026
Cash
$6.71M
Q1 May 2026
Total Debt
$11.98M
Q1 May 2026
Shares Outstanding
36.23M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings